

# ImmunoGuide®

## Instructions for Use

### Antibody to Etanercept ELISA

Enzyme immunoassay for the determination  
of free antibodies to Etanercept in serum and plasma

REF: IG-BB102



12X8



2-8°C



**AYBAYTECH** Biyoteknoloji Ltd. Sti.  
Macun Mah. Batı Blv. ATB İş Merkezi No: 1/285,  
06374-Yenimahalle, Turkey  
Tel : +90 312 397 88 05  
Fax : +90 312 397 88 06  
e-mail: [info@aybaytech.com](mailto:info@aybaytech.com)  
[www.aybaytech.com](http://www.aybaytech.com)

<b><u>Contents</u></b>	<b><u>Page</u></b>
1. Intended Use	2
2. Summary and Explanation	2
3. Principle of the Test	2
4. Warnings and Precautions	2
5. Storage and Stability of the Kit	3
6. Specimen Collection, Handling and Storage	3
7. Contents of the Kit	4
8. Materials Required but not Supplied	4
9. Procedure Notes	4
10. Pre-Test Setup Instructions	5
10.1. Preparation of Components	5
10.2. Dilution of Samples and Calibrators	5
11. Test Procedure	5
11.1. General Remarks	5
11.2. Assay Procedure	6
11.3. Quality Control	6
11.4. Calculation of Results	7
12. Assay characteristics	8
12.1. Specificity	8
12.2. Sensitivity	9
12.3. Precision	10
13. Automation	10
14. References	11

## 1. INTENDED USE

Enzyme immunoassay for the determination of free antibodies to Etanercept in serum and plasma.

## 2. SUMMARY AND EXPLANATION

The drug Etanercept (trade name Enbrel<sup>®</sup>) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. One of the major concerns, despite of its wide usage, is the potential development of anti-drug antibodies (ADA) which in turn may interfere with the drug efficacy as mainly judged by observing the relapse of signs and symptoms of disease and necessitate dose-escalation or potentially ending up the treatment.

The *ImmunoGuide* Antibody to Etanercept ELISA Kit can be used for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug.

## 3. PRINCIPLE OF THE TEST

This *ImmunoGuide* anti-drug antibody(ies) (ADA) kit is a bridging type ELISA for the determination of free antibodies against the drug Etanercept in serum and plasma samples. During the first incubation period, ADA in serum or plasma samples are captured by the drug coated on the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled drug conjugate is added and then incubated. ADA, if present in sample, will make a bridge, with its identical Fab arms, between the drug coated on the well and the other drug molecule labelled with peroxidase. After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with stop solution. The positive reaction is expected to be related to the presence of ADA in the sample.

## 4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact **AybayTech** or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.

5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
6. Chemicals and prepared or used reagents have to be treated as hazardous waste according to the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it has been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

## 5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

## 6. SPECIMEN COLLECTION, HANDLING AND STORAGE

### Serum, Plasma (EDTA, Heparin)\*

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	≤-20°C (Aliquots)	Keep away from heat or direct sun light Avoid repeated freeze-thaw cycles
Stability:	3 d	6 mon	

\* Drug administration/infusion may camouflage/mask the presence of anti-drug antibodies (ADA) in serum/plasma samples. Therefore, blood sampling time is also critical for detection of ADA. It is proposed to obtain blood sample just before administration of the drug.

## 7. CONTENTS OF THE KIT

QUANTITY	COMPONENT
1 x 12 x 8	<b>Microtiter Plate</b> Break apart strips pre-coated with the drug Etanercept.
4 x 1 mL	<b>Anti-Drug Antibody (ADA) Standards A-D</b> 30; 10; 3 and 0 Arbitrary Unit (AU)/mL Used for construction of the standard curve. Contains antibody against drug, preservative and stabilizer. <u>Ready to use.</u>
3 x 0.5 mL	<b>Calibrators 1-3 (10X)</b> Used for set up the cut off. Contains protein matrix / serum.
1 x 30 mL	<b>Dilution Buffer</b> Ready to use. Contains orange dye, proteins and preservative.
1 x 12 mL	<b>Assay Buffer</b> Blue colored. Ready to use. Contains proteins and preservative.
1 x 12 mL	<b>Enzyme Conjugate</b> Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated Etanercept, Proclin <sup>®</sup> and stabilizers.
1 x 12 mL	<b>TMB Substrate Solution</b> Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).
1 x 12 mL	<b>Stop Solution</b> Ready to use. 1 N Hydrochloric acid (HCl).
1 x 50 mL	<b>Wash Buffer, Concentrate (20x)</b> Contains buffer, Tween <sup>®</sup> 20 and Kathon <sup>™</sup> .
2 x 1	<b>Adhesive Seal</b> For sealing microtiter plate during incubation.

## 8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Bidistilled or deionised water and calibrated glasswares.
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm.
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

## 9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate

time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.

3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.

4. Use a pipetting scheme to verify an appropriate plate layout.

5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.

6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.

7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

## 10. PRE-TEST SETUP INSTRUCTIONS

### 10.1. Preparation of Components\*

Dilute/dissolve	Component		Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer	up to 200 mL	Distilled Water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	4 w

\* Prepare Wash Buffer before starting the assay procedure.

### 10.2. Dilution of Calibrators-1, -2, -3 and Samples\*

Calibrators/Sample	To be diluted	With	Remarks
Calibrators 1-3	1:10	Dilution Buffer	For dilution at 1:10 10 µL Calibrator + 90 µL Dilution Buffer
Serum/ Plasma	1:10	Dilution Buffer	For dilution at 1:10 10 µL Serum/Plasma + 90 µL Dilution Buffer
For samples with an OD >Standard A	1:50	Dilution Buffer	For dilution at 1:50 5 µL Sample + 245 µL Dilution Buffer

Standards are ready to use and should NOT be diluted with the dilution buffer.

## 11. TEST PROCEDURE

### 11.1. GENERAL REMARKS

11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.

11.1.2. All Standards should be run with each series of unknown samples.

11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.

11.1.4. All steps of the test should be completed without interruption.

11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.

## 11.2. ASSAY PROCEDURE

1.	Pipette <b>100 µL</b> of <b>Assay Buffer</b> into each of the wells to be used.																
2.	<p>Pipette <b>50 µL</b> of each <b>Ready-to-Use Standards and 1:10 Diluted Calibrators-1, -2, -3 and Samples (as described in section 10.2)</b> into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided.</p> <p style="text-align: center;"><u>Wells</u></p> <table style="margin-left: 40px;"> <tr> <td>A1:</td> <td>Standard A</td> </tr> <tr> <td>B1:</td> <td>Standard B</td> </tr> <tr> <td>C1:</td> <td>Standard C</td> </tr> <tr> <td>D1:</td> <td>Standard D</td> </tr> <tr> <td>E1:</td> <td>Calibrator-1</td> </tr> <tr> <td>F1:</td> <td>Calibrator-2</td> </tr> <tr> <td>G1:</td> <td>Calibrator-3</td> </tr> <tr> <td>H1 and so on:</td> <td>Samples (Serum/Plasma)</td> </tr> </table>	A1:	Standard A	B1:	Standard B	C1:	Standard C	D1:	Standard D	E1:	Calibrator-1	F1:	Calibrator-2	G1:	Calibrator-3	H1 and so on:	Samples (Serum/Plasma)
A1:	Standard A																
B1:	Standard B																
C1:	Standard C																
D1:	Standard D																
E1:	Calibrator-1																
F1:	Calibrator-2																
G1:	Calibrator-3																
H1 and so on:	Samples (Serum/Plasma)																
3.	Cover the plate with adhesive seal. Shake plate carefully by tapping several times. <b>Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C).</b>																
4.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate <b>5 X 350 µL</b> of <b>Diluted Wash Buffer</b> per well. Remove excess solution by tapping the inverted plate on a paper towel.																
5.	Pipette <b>100 µL</b> of <b>Enzyme Conjugate</b> (HRP-drug) into each well.																
6.	Cover plate with adhesive seal. Shake plate carefully. <b>Incubate 60 min</b> at RT.																
7.	Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate <b>5 X 350 µL</b> of <b>Diluted Wash Buffer</b> per well. Remove excess solution by tapping the inverted plate on a paper towel.																
8.	Pipette <b>100 µL</b> of Ready-to-Use <b>TMB</b> Substrate Solution into each well.																
9.	<b>Incubate 15 min</b> at RT. Avoid exposure to direct sunlight.																
10.	Stop the substrate reaction by adding <b>100 µL</b> of <b>Stop Solution</b> into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow.																
11.	Measure optical density (OD) with a photometer at <b>450 nm</b> within <b>15 min</b> after pipetting the Stop Solution.																

### 11.3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.

## 11. 4. CALCULATION OF RESULTS

Different sera (negative for anti-drug antibody (ADA) ) were screened and all ranged up to near twofold of the OD450 nm created by each of the calibrators 1-3 (each was composed by pooling ADA-negative sera).

In order to avoid a false positive result, a secure range/threshold (defined as the cut-off value) was determined based on the study indicated above.

### 11.4.1 Qualitative Interpretation

**11.4.1.1. The results are evaluated by dividing each individual OD results by the Cut-off Value. Cut-off Value is determined as described below:**

**The Mean OD450nm of Calibrator 1-3 = (OD450nm of Calibrator 1+ OD450nm of Calibrator 2+ OD450nm of Calibrator 3) / 3**  
**(The sum OD450nm of calibrators is divided by 3)**

**Cut-off Value = 2 x the mean OD450 nm of Calibrator 1-3**

**11.4.1.2.** If the “Sample OD450nm” is less (<) than the “Cut-off Value”, the sample is regarded as NEGATIVE for Anti-Drug-Antibody (ADA) specific for the drug in concern.

**11.4.1.3.** If the “Sample OD450nm” is equal and higher ( $\geq$ ) than the “Cut-off Value”, the sample is regarded as POSITIVE for Anti-Drug-Antibody (ADA) specific for the drug in concern. And if required, samples may be plotted on standard curve for quantitative analysis.

Range	Interpretation
$\geq$ Cut-off Value	POSITIVE
< Cut-off Value	NEGATIVE

### 11.4.2 Quantitative Calculation

**11.4.2.1.** The lowest positive standard (standard C) is adjusted with an OD450nm just higher than threefold of the cut-off value and arbitrarily assigned as 3 AU/mL.

**11.4.2.2.** The results are expressed in arbitrary units (AU/mL).

**11.4.2.3.** A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 values (Y-axis). Construct a standard curve of difference data using software capable of generating four-parameter logistic (4PL) or point-to-point calculation curve fit.

**11.4.2.4.** To obtain the exact values of the samples, the concentration determined from the standard curve should be multiplied by the dilution factor.

**11.4.2.5.** Samples generating absorbance values greater than that of the highest standard should be further diluted using the dilution buffer and then reanalyzed. Also this second dilution has to be used for calculation of the final result.

**11.4.2.6.** Results lower than the analytical sensitivity level (2 AU/mL) is evaluated as standing in the “Gray Zone”. If the sample is a real ADA positive and still in the gray zone, then it should be re-tested with a new sample obtained just before the next time of drug administration.



## 12. ASSAY CHARACTERISTICS

### 12.1. SPECIFICITY

The detection of ADA formation is highly dependent on the sensitivity and specificity of the assay used.


The initial screening assay should be sensitive to low and high-affinity ADA. Endogenous and exogenous components in serum or plasma may influence assay results. Measuring immune responses to therapeutic protein products that possess Ig tails, such as mAb and Fc-fusion proteins, may be particularly difficult when RF is present in serum or plasma. RF is generally an IgM antibody that recognizes IgG, although other Ig specificities have been noted. Therefore, there is frequently a need to dilute patient samples and to make approach for minimizing interference from RF to maintain a reasonable ability to detect ADA. However, dilution and/or addition of RF-blocking reagents may not solve all potential interference related with matrix components contributing to non-specific signal in samples.

If the serum/plasma sample of a patient, a candidate for a specific monoclonal drug treatment, is negative at the time before starting drug therapy and become positive during treatment, it could be concluded that the induction of the specific ADA is suspected in this individual. As shown in Figure 1, the true positive reaction of the sample is inhibited by pre-incubation of the sample with the specific drug itself (samples are spiked with certain amount of drug). However, inhibition was not observed in false positive reaction related with other components in sample (Figure 1).

Based on the approach used in calculating the assay cut-off value of anti-drug antibody (ADA) ELISAs, approximately 1-5% of tested samples are expected to generate false-positive ADA response during initial screening analysis. Therefore, further confirmation of the specificity of the ADA activity in the samples, identified as positive, is also recommended by recent publications. In addition, the FDA released a guidance paper on immunogenicity testing of therapeutic proteins: (<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf>)

In order to further confirm the specificity of the ADA positive signal, ImmunoGuide suggests a "Confirmatory Assay (competitive drug inhibition test)": Confirmatory Assay is performed by retesting the positive sample after dilution, at 1:10 as before, with phosphate buffered solution or kit's dilution buffer containing the drug in concern at a concentration of 50µg/mL that is exogenously added by the researcher.

Figure 1.



## 12.2. SENSITIVITY


Generally, the sensitivity of the ADA assay is calculated as the lowest concentration of the positive control that can consistently generate a positive signal. However, as shown in Figure 2 below, data obtained at the *ImmunoGuide* Laboratory, the assay sensitivity also differs significantly depending on the high vs low affinity antibody used for the construction of the standard curve in the assay system. For example, when an immunoaffinity-purified ADA was exogenously added to serum, it was observed that the lowest detectable level that can be clearly distinguished from the negative control value is somewhere around 10ng/mL. It is much more lower when mAb2 is used instead.

In any case this number is highly depending on the characteristics of the ADA under investigation (e.g. affinity). Therefore this number may be significantly different for each individual sample under investigation.

Considering the fact that the antibodies under investigation are polyclonal ones, the affinities can be very different for each single sample. Therefore any attempt for a quantification of the results by a general standard curve also is very questionable (Figure 2). This is why we are giving the results in arbitrary units only.

Analytical sensitivity level is determined as 2 AU/mL and corresponding to the detection limit (limit of quantification) of 20 AU/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:10 before starting the assay.

Figure 2.



### 12.3. PRECISION OF THE KIT

Intra-assay CV: <10%.

Inter-assay CV: <10%

### 13. AUTOMATION

The *ImmunoGuide* Anti Drug Antibody (ADA) ELISA kits are suitable also for being used by an automated ELISA processor.

**14. REFERENCES**

1. Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-  $\alpha$  contents and by stimulating newly formed neurogenesis. *Mediators Inflamm*. 2013;2013:620837. doi: 10.1155/2013/620837.
2. Jung YS, Park W, Na K. Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis. *J Control Release*. 2013 Oct 28;171(2):143-51.
3. Erdemli Ö, Özen S, Keskin D, Usanmaz A, Batu ED, Atilla B, Tezcaner A. In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. *J Biomater Appl*. 2014 Oct;29(4):524-42.
4. Chen DY, Chen YM. Response to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al. *Ann Rheum Dis*. 2015;74(8):e43. doi: 10.1136/annrheumdis-2015-207543.
5. Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. *Arthritis Rheumatol*. 2015 May;67(8):2011-9.
6. Kneepkens EL, Kriekaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T, Wolbink GJ. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. *Ann Rheum Dis*. 2015 Oct;74(10):1825-9.
7. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, Hung WT, Lan JL. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. *Ann Rheum Dis*. 2015 Mar;74(3):e16. doi: 10.1136/annrheumdis-2013-203893.
8. Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. *Ann Rheum Dis*. 2014 Jun;73(6):1138-43.
9. Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. *Br J Dermatol*. 2013 Aug;169(2):306-13.
10. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, Maverakis E. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. *Clin Rev Allergy Immunol*. 2013;44(2):121-40.
11. Hutmacher MM, Nestorov I, Ludden T, Zitnik R, Banfield C. Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. *J Clin Pharmacol*. 2007;47(2):238-48.